PRIM2: A Marker of MYC-driven Hyper-proliferation, Disease Progression, Tumor Aggressiveness and Poor Survival in Glioma Patients
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.DNA primase 2 (PRIM2) is a key metabolic driver in gliomas, linked to MYC-driven cell cycle progression and poor patient survival. This finding offers a potential marker for aggressive brain tumors.
Area Of Science
- Oncology
- Molecular Biology
- Genetics
Background
- Gliomas, the most common brain tumors, exhibit metabolic alterations crucial for their progression.
- The intricate relationship between metabolic changes and cellular mechanisms driving glioma initiation, progression, and aggressiveness is not fully understood.
Purpose Of The Study
- To investigate the role of metabolic alterations in glioma progression and aggressiveness.
- To identify specific metabolic genes and cellular mechanisms associated with poor glioma outcomes.
Main Methods
- Differential gene expression analysis of metabolism-related genes in glioma patient data from The Cancer Genome Atlas (TCGA).
- Pathway and gene set enrichment analysis (GSEA), transcription factor prediction, network construction, and correlation analyses.
- Validation using independent Gene Expression Omnibus (GEO) datasets and survival analysis.
Main Results
- Five metabolism-related genes were identified, correlating with glioma aggressiveness.
- Cell cycle progression and hyper-proliferation were confirmed as key drivers of glioma progression.
- DNA primase 2 (PRIM2) was identified as a critical metabolic gene directly associated with cell cycle progression and regulated by the MYC transcription factor.
- PRIM2 expression independently predicts MYC-driven cell cycle progression, tumor aggressiveness, and poor survival in glioma patients.
Conclusions
- PRIM2 serves as a significant marker for MYC-driven cell cycle progression and hyper-proliferation in gliomas.
- PRIM2 expression is indicative of disease onset, progression, tumor aggressiveness, and unfavorable survival outcomes in glioma patients.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...